Plain-English translation of NCT04575935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The LANCE trial is testing whether minimally invasive surgery (using small incisions and a camera) works as well as traditional open surgery for removing cancer after in women with advanced ovarian, fallopian tube, or primary peritoneal cancer. You would have already received 3 to 4 cycles of before the surgery. The goal is to see if the smaller incision approach gives patients the same cancer control while potentially causing less pain and helping you recover faster.
Minimally invasive surgery causes less pain, shorter hospital stays, and faster recovery than traditional open surgery—but doctors want to make sure it's safe and effective for removing all possible cancer in advanced cases. This trial will answer that important question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either minimally invasive surgery or traditional open surgery after completing your . The surgery will happen within 6 weeks of your last dose. After surgery, you will receive additional as standard treatment. You will have follow-up visits to check your health, discuss how you are feeling, and have imaging scans to monitor for cancer recurrence. The study tracks your surgery outcomes, recovery, quality of life, and long-term survival.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States